Harrow, Inc. · NASDAQ:HROW
Harrow — Harrow Health — Investor Presentation (November 2020)
15 slides from Harrow's investor presentation, Nov 17, 2020
Slide 1: Harrow cover: shares outstanding and market capitalization
HARROW NASDAQ: HROW OUTSTANDING COMMON STOCK: 25.7M SHARES ESTIMATED MARKET CAPITALIZATION: $175M PRICE PER SHARE as of Nov. 16, 2020: $6.81
Slide 2: Safe Harbor
HARROW SAFE HARBOR This presentation contains express “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying
Slide 3: We are a growing U.S. leader in the eyecare pharmaceuticals market
HARROW We are a growing U.S. leader in the eyecare pharmaceuticals market. We focus on the surgical and chronic eyecare markets. We founded ImprimisRx, Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals. We own royalty rights on clinical stage drug candidates in development by busin
Slide 4: Financial Growth: Revenues, Assets, and Gross Margins
Financial Growth: Revenues, Assets, and Gross Margins $70,000 (Revenue and Assets in Thousands) $60,000 pe $50,000 $40,000 $30,000 $20,000 $10,000 $0 2014 2015 2016 2017 2018 2019 Adj.E(L)BITDA —($7.5M) ($10M) ($10M) ($7M) $0.2M $4.6M Wim Consolidated Revenues MmAssets == Gross Margins HARROW
Slide 5: COVID Revenue Recovery
COVID Revenue Recovery Quarterly revenues are now ahead of the last pre-COVID normalized quarterly period $16,000,000 $14,000,000 Mandated limitations on elective surgeries | $12,000,000 $10,000,000 $8,000,000 $6,000,000 $4,000,000 $2,000,000 $- : n 4th Qtr-19 Ist Qtr - 20 2nd Qtr - 20 3rd Qtr - 20
Slide 6: ImprimisRx
IMpPriMIs p . * 100% wholly-owned Harrow subsidiary founded in 2014. + The leading FDA-registered cGMP ophthalmic pharmaceutical drug compounder. + Products serve the surgical, dry eye disease, and glaucoma markets. + Peer-reviewed medical literature supports all ImprimisRx product lines; 60+ patent
Slide 7: Size of Key U.S. Ophthalmic Markets
ARROW imprimis Size of Key U.S. Ophthalmic Markets 5,000,000+ 16,000,000+ Annual Ophthalmic Surgeries 000,000 Dry Eye Disease Patients Glaucoma Patien Annual Ophthalmic Surgery estimates from internal data (e.g. include cataract, LASIK, and glaucoma) Glaucoma Patients estimates: https://www.cdc.gov/
Slide 8: Traditional Pharmaceutical Value Chain
Traditional Pharmaceutical Value Chain oe eee o- MD/Hospital PRODUCTION PHARMACY INSURERS WHOLESALERS PHARMACY Prescription BENEFIT RETAILERS MD OFFICE, MANAGERS pie OR Middle-men and intermediaries thrive. Inefficiencies diminish value for the patient, pharmaceutical company, and the healthcare pro
Slide 9: ImprimisRx Value Chain
ImprimisRx Value Chain — (A) PATIENT ORDER & (@) PAYMENT > MD OFFICE, —=- HOSPITAL OR ASC Cash-pay focused; no pharmacy benefit manager (PBM), wholesaler or distributor middlemen. No formulary rejections, discount cards, prior authorizations, insurance investigations, or PBM claw-backs. The Imprimis
Slide 10: ImprimisRx and EyePoint Dexycu agreement
IMmprimis Ree ® EYEPOINT PHARMACEUTICALS. Background + In August of 2020, we entered into an agreement to promote EyePoint’s Dexycu® to our customers. * Dexycu is the first and only FDA approved single dose, sustained release, intracameral steroid (9% dexamethasone) injection for the treatment of po
Slide 11: ImprimisRx is evolving beyond compounding
IMpPriMIs p . ImprimisRx is evolving beyond compounding. Growth Strategy ¢ Build on customer goodwill to expand sales depth within existing and new accounts. * Continue to develop innovative products based on customer feedback and requests. * Commercial partnerships (e.g. Dexycu) drive new revenues;
Slide 12: ImprimisRx formulations have helped birth companies
ImprimisRx formulations have helped birth 3 companies elon PHARMACEUTICALS Orphan-disease focused pharmaceutical company with a growing pipeline. Carved out of Harrow in June 2017, NASDAQ IPO in November 2018 (ETON). Harrow Health owns 3.5M shares of Eton common stock (~17%). G@urtace Clinical-stage
Slide 13: Over $50 Million in Non-Control Equity Positions
HARROW Over $50 Million* in Non-Control Equity Positions elon PHARMACEUTICALS G@urtace melt PHARMACEUTICALS VC/PE-backed Melt $17,500,000 NASDAG-listed Eton $26,000,000 VC-backed Surface $11,550,000 “Melt/Surface equity values estimated based on the conversion price of Series A preferred stock (the
Slide 14: Harrow owns 100% of ImprimisRx, a cornerstone commercial drug platform
HARROW Harrow owns 100% of ImprimisRx, a cornerstone ophthalmic-focused commercial drug platform. We expect ImprimisRx to grow beyond a $100M revenue business over the next few years. We intend to leverage the ImprimisRx platform to partner and inorganically expand our business. Positioned to captur
Slide 15: Woodmont Blvd. Ste
HARROW 102 Woodmont Blvd. Ste 610 Nashville, Tennessee 37205 (615) 733-4730 IR@HARROWINC.COM WWW.HARROWINC.COM
Harrow Health — Investor Presentation (November 2020) on 6ix